###begin article-title 0
###xml 168 172 <span type="species:ncbi:10116">rats</span>
Activation of estrogen receptor beta-dependent nitric oxide signaling mediates the hypotensive effects of estrogen in the rostral ventrolateral medulla of anesthetized rats
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Apart from their well-known peripheral cardiovascular effects, emerging evidence indicates that estrogen acts as a modulator in the brain to regulate cardiovascular functions. The underlying mechanisms of estrogen in central cardiovascular regulation, however, are poorly understood. The present study investigated the cardiovascular effects of 17beta-estradiol (E2beta) in the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons are located, and delineated the engagement of nitric oxide (NO) in E2beta-induced cardiovascular responses.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 8 27 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
In male Sprague-Dawley rats maintained under propofol anesthesia, the changes of blood pressure, heart rate and sympathetic vasomotor tone after microinjection bilaterally into the RVLM of a synthetic estrogen, E2beta were examined for at least 120 min. The involvement of ERalpha and/or ERbeta subtypes was determined by microinjection of selective ERalpha or ERbeta agonist into bilateral RVLM. Different NO synthase (NOS) inhibitors were used to evaluate the involvement of differential of NOS isoforms in the cardiovascular effects of E2beta.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 546 549 534 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bis</italic>
###xml 743 747 727 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tris</italic>
###xml 910 911 894 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 911 912 895 896 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G</sup>
Bilateral microinjection of E2beta (0.5, 1, or 5 pmol) into the RVLM dose-dependently decreased systemic arterial pressure (SAP) and the power density of the vasomotor components of SAP signals, our experimental index for sympathetic neurogenic vasomotor tone. These cardiovascular depressive effects of E2beta (1 pmol) were abolished by co-injection of ER antagonist ICI 182780 (0.25 or 0.5 pmol), but not a transcription inhibitor actinomycin D (10 nmol). Like E2beta, microinjection bilaterally into the RVLM of a selective ERbeta agonist 2,3-bis(4-hydroxyphenyl) propionitrile (DPN, 1, 2, or 5 pmol) induced significant decreases in these hemodynamic parameters in a dose-dependent manner. In contrast, the selective ERalpha agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (5 pmol) did not influence the same cardiovascular parameters. Co-administration bilaterally into the RVLM of NOS inhibitor NG-nitro-L-arginine methyl ester (5 nmol) or selective inducible NOS (iNOS) inhibitor S-methylisothiourea (25 pmol), but not selective neuronal NOS inhibitor 7-nitroindazole (0.5 pmol) or endothelial NOS inhibitor N5-(1-Iminoethyl)-L-ornithine (2.5 pmol), significantly attenuated the cardiovascular depressive effects elicited by DPN (2 pmol).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Our results indicate that E2beta in the RVLM elicited short-term cardiovascular depressive effects via an ERbeta-dependent nontranscriptional mechanism. These vasodepressor effects of E2beta are likely to be mediated by the iNOS-derived NO in the RVLM.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 170 171 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 322 323 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 578 579 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 580 581 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Most known biological effects of estrogen, a major female gonadal steroid, are mediated by binding of the hormone to estrogen receptor (ER) subtypes, ERalpha and ERbeta [1]. The ERs belong to a member of the nuclear hormone family of intracellular receptors that function as ligand-dependent transcriptional coactivators [1]. Upon binding to nuclear ERs, estrogen and ER forms a complex to bind at specific response elements in the promoters of target genes where it regulates gene transcription through direct interactions with DNA or other transcriptional machinery proteins [1,2]. This transcriptional mode of action is responsible for the well defined, long-lasting cellular responses of estrogen.
###end p 11
###begin p 12
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 248 249 248 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 291 292 291 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 549 550 549 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 551 552 551 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Recent studies have demonstrated that activated ER may promote physiological functions via nontranscriptional mechanisms [1,3,4]. In the heart and vasculature, the nongenomic mechanisms underlie estrogen-induced short-term arterial vasodilation [4,5], inhibition of atherosclerotic lesions [4,6] and amelioration of ischemia/reperfusion-induced cardiac injury [7]. These estrogen-triggered rapid cardiovascular responses are thought to be mediated via direct activation by the hormone of the cellular membrane rather than intracellular receptors [3,4,8].
###end p 12
###begin p 13
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 790 792 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 313 317 <span type="species:ncbi:10116">rats</span>
###xml 366 370 <span type="species:ncbi:10116">rats</span>
###xml 393 397 <span type="species:ncbi:10116">rats</span>
Apart from their well-known peripheral cardiovascular effects, emerging evidence indicates that estrogen acts as a modulator in the brain to regulate cardiovascular functions [9-14]. Intracerebroventricular injection of estrogen increases systemic arterial pressure (SAP) and sympathetic nerve activity in female rats [9]. In estrogen-replaced ovariectomized female rats [12], but not in male rats [11], peripheral injection of estrogen decreases baseline sympathetic tone and SAP, which are antagonized by central injection of the selective ER antagonist [11,12]. Within the brain stem, both ER mRNA [15] and protein [16,17] are distributed in neurons of the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons for the maintenance of basal vasomotor tone are located [18], making this nucleus a candidate substrate to subserve the central cardiovascular regulatory actions of estrogen. Only a few studies [13,14] reported the cardiovascular regulatory actions of estrogen in the RVLM. Moreover, the underlying mechanisms mediating central cardiovascular effects of estrogen are not fully understood. The present study was therefore undertaken to evaluate the hypothesis that estrogen in the RVLM participates in neural regulation of cardiovascular functions via ERbeta-dependent mechanisms that entail activation of nitric oxide (NO) signaling.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Animals
###end title 15
###begin p 16
###xml 43 62 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 189 193 <span type="species:ncbi:10116">rats</span>
###xml 321 325 <span type="species:ncbi:10116">rats</span>
###xml 331 335 <span type="species:ncbi:10116">rats</span>
###xml 488 502 <span type="species:ncbi:10116">laboratory rat</span>
Experiments were carried out in adult male Sprague-Dawley rats (250-300 g, n = 126) purchased from the Experimental Animal Center of the National Science Council (Taipei, Taiwan). The male rats were chosen in this study to avoid possible confounding influence from differing circulating estrogen levels in cycling female rats. All rats were kept under conditions of constant temperature (23 +/- 0.5degreesC) with a standard 12 h light-dark cycle (08:00-20:00) and free access to standard laboratory rat chow (Purina) and tap water. They were allowed to acclimatize for at least 7 days before experimental manipulations. All experiment procedures were conducted in compliance with the guidelines of our institutional animal care committee. All efforts were made to reduce the numbers of animals used and to minimize animal suffering during the experiment.
###end p 16
###begin title 17
General animal preparation
###end title 17
###begin p 18
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 414 416 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1057 1059 1057 1059 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
The preparatory surgery including intubation of the trachea and cannulation of the femoral artery and both femoral veins was performed under an induction dose of pentobarbital sodium (50 mg/kg, i.p.) [19,20]. During recording session, the anesthetic maintenance of the animals was achieved by an intravenous infusion of propofol (Zeneca Pharmaceuticals, Macclesfield, UK) at 20-30 mg/kg/h. This management scheme [21] provides satisfactory anesthetic maintenance while preserving the capacity of neural control of cardiovascular functions. The same management scheme also has no significant effect in increasing respiratory resistance [22] or airway mucus secretion [23]. Animals also received neuromuscular blockade with intravenous infusion of pancuronium (2 mg/kg/h) via the femoral vein. Pulsatile and mean SAP (MSAP), as well as heart rate (HR), was recorded on a polygraph (Gould RS3400, Valley View, OH, USA). Animals were ventilated mechanically by the use of a small rodent ventilator (Harvard 683, South Natik, MA, USA) to maintain an end-tidal CO2 within 4.0-4.5%, as monitored by a capnograph (Datex Normocap, Helsinki, Finland). This procedure was conducted to minimize possible confounding cardiovascular changes secondary to respiratory perturbation. The head of the animal was thereafter fixed to a stereotaxic headholder (Kopf 1430, Tujunga, CA, USA), and the rest of the body was placed on a thermostatically controlled pad to maintain rectal temperature of 37 +/- 0.5degreesC. All data were collected from animals with a steady baseline MSAP above 90 mmHg throughout the recording period.
###end p 18
###begin title 19
Recording and power spectral analysis of SAP signals
###end title 19
###begin p 20
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 363 365 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 459 461 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
The SAP signals recorded from the femoral artery were simultaneously subject to on-line power spectral analysis as detailed previously [21,24]. We were particularly interested in the very low-frequency (0-0.25 Hz) and low-frequency (0.25-0.8 Hz) components of the SAP spectrum. These spectral components of SAP signals were reported to take origin from the RVLM [25] and their power density reflect the prevailing sympathetic neurogenic vasomotor tone [19-21,26]. The power densities of these two spectral components were displayed during the experiment, alongside SAP, MSAP and HR, in an online and real-time manner.
###end p 20
###begin title 21
Microinjection of test agents into the RVLM
###end title 21
###begin p 22
###xml 726 728 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 743 745 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 746 748 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 843 845 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
Microinjection bilaterally of test agents into the functionally identified RVLM sites were performed stereotaxically and sequentially with a glass micropipette (external tip diameter: 50-80 mum) connected to a 0.5-mul Hamilton microsyringe (Reno, NV, USA). A total volume of 50 nl was delivered to each side over 1-2 min to allow for complete diffusion of the injected solution. The time between injections from one side of the RVLM to the other was 5-6 min. The stereotaxic coordinates for the RVLM were 4.5 to 5.0 mm posterior to lambda, 1.8 to 2.1 mm lateral to midline, and 8.0 to 8.5 mm below the dorsal surface of the cerebellum. These coordinates were selected to cover the ventrolateral medulla in which both ER mRNA [15] and protein [16,17] are distributed, and where functionally identified sympathetic premotor neurons are located [18].
###end p 22
###begin p 23
At the beginning of each experiment, the functional location of RVLM neurons on either side was established by monitoring a transient pressor response (15-25 mmHg) after microinjection of L-glutamate (1 nmol, Sigma Chemical). Subsequent microinjections of test agents were delivered to the identified pressor loci 20 min after the completion of glutamate application. This time lag was introduced to ensure complete recovery from the glutamate-induced pressor response before microinjection bilaterally into the RVLM of test agents or vehicle.
###end p 23
###begin p 24
###xml 320 321 320 321 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 331 332 331 332 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 342 343 342 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 345 346 345 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 356 357 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
All microinjection solutions contained 1% Evans blue to aid in subsequent histological verification of the injection site. Possible volume effect of microinjection was controlled by injecting the same amount of artificial cerebrospinal fluid (aCSF, pH 7.4) of the following composition (in mM): 126 NaCl, 2.5 KCl, 2 CaCl2, 1-2 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose. To avoid confounding effects of drug interactions, each animal received only one treatment of synthetic estrogen, selective ERalpha, ERbeta agonist or vehicle, given alone or in combination with one test agent.
###end p 24
###begin title 25
Preparation of test agents
###end title 25
###begin p 26
###xml 164 168 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tris</italic>
###xml 280 283 267 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bis</italic>
###xml 647 648 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 648 649 620 621 <sup xmlns:xlink="http://www.w3.org/1999/xlink">G</sup>
###xml 1141 1143 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1144 1146 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
The test agents were used in this study included 17beta-estradiol-3-sulphate sodium (E2beta; Sigma-Aldrich, St. Louis, MO, USA); a selective ERalpha agonist, 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT; Tocris Cookson Inc., Bristol, UK); a selective ERbeta agonist, 2,3-bis(4-hydroxyphenyl) propionitrile (DPN; Tocris Cookson); 17alpha-estradiol (E2alpha; Sigma-Aldrich); a nonspecific ER antagonist, ICI 182780 (Tocris Cookson); a selective ERalpha antagonist, methyl-piperidino-pyrazole (MPP; Tocris Cookson); a selective ERbeta antagonist, R,R-tetrahydrochrysene (R,R-THC; Tocris Cookson); a nonselective NO synthase (NOS) inhibitor, NG-nitro-L-arginine methyl ester (L-NAME; Sigma-Aldrich); a selective inducible NOS (iNOS) inhibitor, S-methylisothiourea (SMT; Tocris Cookson); a selective neuronal NOS (nNOS) inhibitor, 7-nitroindazole (7-NI; Tocris Cookson); a selective endothelial NOS (eNOS) inhibitor, N5-(1-Iminoethyl)-L-ornithine (L-NIO; Tocris Cookson); or a transcription inhibitor, actinomycin D (AMD; Tocris Cookson). The dose and treatment scheme were adopted from our preliminary experiments and previous studies [20,26], which used the same test agents for the same purpose as in this study. Moreover, to avoid confounding cardiovascular effects evoked by individual test agent, we purposely selected dose that did not alter the baseline circulatory parameters when microinjected alone into the bilateral RVLM. The dose of each antagonist or inhibitor used in this study, nonetheless, has been shown in our pilot studies to significantly inhibit cardiovascular responses induced by its specific ligand. All test agents were dissolved in aCSF at pH 7.4, with the exception of ICI 182780 and 7-NI, which used, respectively, 5% dimethyl sulfoxide (DMSO) or 3% methanol as the solvent. Control experiments showed that these vehicles had no significant effect on baseline MSAP or HR during the 120 min observation period.
###end p 26
###begin title 27
Brain histology
###end title 27
###begin p 28
At the conclusion of each experiment, the animal was killed by an overdose of pentobarbital sodium, and the brain stem was removed from animals and fixed in 30% sucrose in 10% formaldehyde-saline solution for at least 72 h. Histological verification of the location of microinjection sites was carried out on frozen 25-mum sections of the medulla oblongata stained with 1% Neutral red.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 331 340 329 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post hoc </italic>
###xml 449 450 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 457 459 455 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
All values are expressed as mean +/- SEM. The two-way analysis of variance (ANOVA) with repeated measures was used to assess group difference in the effect of various treatments on time course of changes in MSAP, HR or power density of vasomotor components of SAP spectrum. This was followed by the Scheffe multiple-range test for post hoc assessment of individual means. The maximal changes in the hemodynamic parameters were evaluated with paired t-test. P < 0.05 was considered statistically significant.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
Cardiovascular effects of microinjection bilaterally into the RVLM of E2beta
###end title 32
###begin p 33
###xml 330 332 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 333 335 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 336 338 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 377 378 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1031 1032 1012 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1544 1545 1513 1514 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Compared to aCSF treatment, microinjection bilaterally into the functionally identified pressor region of RVLM of E2beta (0.5, 1, or 5 pmol) resulted in significant and dose-dependent decreases in MSAP and power density of vasomotor components of SAP spectrum, our experimental index for sympathetic neurogenic vasomotor outflow [19-21,24], without apparent effect on HR (Fig. 1). The cardiovascular depressive responses of E2beta commenced approximately 30 min, and lasted for at least 120 min posttreatment. Duration of cardiovascular depressive responses of E2beta (0.5, 1, or 5 pmol) was dose dependent. At a lower dose (0.5 pmol), E2beta promoted vasodepressor responses that lasted for approximately 150 min postinjection, whereas at higher doses (1 or 5 pmol) E2beta produced cardiovascular depressive responses that sustained more than 3-4 hrs postinjection. Microinjection bilaterally into the RVLM of the inactive isomer of estrogen, E2alpha (5 pmol), on the other hand, did not affect basal hemodynamic parameters (Fig. 1). Microinjection of E2beta (5 pmol) into the ventrolateral medullary areas adjacent to, but outside the confine of RVLM, e.g., spinal trigeminal nucleus or lateral paragigantocellular nucleus, also elicited minimal effects on those cardiovascular parameters (data not shown). In addition, intravenous injection of a high dose (5 pmol) E2beta did not affect baseline MSAP, HR or power density of vasomotor components of SAP spectrum (MSAP: -3.2 +/- 1.6 mmHg; HR: +4.3 +/- 0.8 bpm; SAP spectrum: -0.6 +/- 0.5 mmHg2, n = 3).
###end p 33
###begin p 34
###xml 0 79 0 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cardiovascular effects after microinjection bilaterally into the RVLM of E2&#946;</bold>
###xml 600 602 581 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 288 292 <span type="species:ncbi:10116">rats</span>
Cardiovascular effects after microinjection bilaterally into the RVLM of E2beta. Time-course of the changes in mean systemic arterial pressure (MSAP), heart rate (HR) and total power density of vasomotor components (0-0.8 Hz) of systemic arterial pressure (SAP) spectrum in anaesthetized rats that received microinjection bilaterally into the rostral ventrolateral medulla (RVLM, at time 0) of artificial cerebrospinal fluid (aCSF), 17beta-estradiol (E2beta, 0.5, 1 or 5 pmol), or 17alpha-estradiol (E2alpha, 5 pmol). Values are presented as mean +/- S.E.M., n = 6-8 animals per experimental group. *P < 0.05 versus corresponding aCSF group in the Scheffe multiple range test.
###end p 34
###begin title 35
Effects of ER antagonist on the E2beta-induced cardiovascular depressive responses
###end title 35
###begin p 36
###xml 182 183 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 820 822 791 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 932 934 893 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1189 1190 1150 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1468 1470 1416 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Co-administration bilaterally into the RVLM of a nonspecific ER antagonist, ICI 182780 (0.25 or 0.5 pmol) attenuated the cardiovascular depressive responses of E2beta (1 pmol) (Fig. 2) in a dose-related manner. At high dose (0.5 pmol), ICI 182780 almost completely reversed the E2beta-induced hypotension and the decrease in sympathetic vasomotor tone. Comparable results were obtained in animals that received ICI 182780 delivered at 20 min before E2beta microinjection (data not shown). In addition, co-administration bilaterally into the RVLM of a specific ERbeta antagonist R,R-THC (50 pmol), but not a specific ERalpha antagonist MPP (1 nmol), attenuated the vasodepressor responses induced by E2beta (1 pmol) (maximal decrease in MSAP: E2beta alone: -48.6 +/- 6.3 mmHg vs. E2beta+R,R-THC: -18 +/- 6.1 mmHg, n = 4, P < 0.05; maximal decrease in MSAP: E2beta alone: -48.6 +/- 6.3 mmHg vs. E2beta+MPP: -50.3 +/- 5.4 mmHg, n = 4, P > 0.05). Microinjection bilaterally into the RVLM of ICI 182780 (0.25 or 0.5 pmol), R,R-THC (50 pmol) or MPP (1 nmol) alone, on the other hand, had no discernible effect on baseline MSAP, HR or power density of vasomotor components of SAP spectrum (Table 1). In contrast, co-administration bilaterally into the RVLM of a transcription inhibitor AMD (10 nmol), did not affect the cardiovascular depressive response of E2beta (1 pmol) (maximal decrease in MSAP: E2beta alone: -46.8 +/- 5.3 mmHg vs. E2beta+AMD: -52 +/- 6.5 mmHg, n = 6, P > 0.05).
###end p 36
###begin p 37
###xml 0 82 0 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of ER antagonist on the E2&#946;-induced cardiovascular depressive responses</bold>
###xml 506 507 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 211 215 <span type="species:ncbi:10116">rats</span>
Effects of ER antagonist on the E2beta-induced cardiovascular depressive responses. Time-course of the changes in MSAP and total power density of vasomotor components (0-0.8 Hz) of SAP spectrum in anaesthetized rats that received microinjection bilaterally into the RVLM (at time 0) of aCSF, or E2beta (1 pmol) given together with ICI 182780 (ICI, 0.25 or 0.5 pmol) or 5% DMSO. Values are presented as mean +/- S.E.M., n = 6-8 animals per experimental group. *P < 0.05 versus corresponding aCSF group, and #P < 0.05 versus corresponding E2beta+DMSO group in the Scheffe multiple range test.
###end p 37
###begin p 38
Effects of test agents on baseline MSAP, HR and power density of vasomotor components of SAP spectrum
###end p 38
###begin p 39
###xml 134 135 132 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Values are mean +/- S.E.M., n = 6-7 animals per experimental group. No significant difference was detected among groups in the paired t-test.
###end p 39
###begin title 40
Cardiovascular effects of microinjection bilaterally into the RVLM of ERalpha or ERbeta agonist
###end title 40
###begin p 41
###xml 420 421 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 832 833 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1058 1059 1025 1026 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
To decipher the role of ERalpha and/or ERbeta subtypes in E2beta-induced cardiovascular depressive responses, we evaluated the cardiovascular effects of the selective ERalpha or ERbeta agonist in the RVLM. Similar to effects induced by E2beta, microinjection bilaterally into the RVLM of ERbeta agonist DPN (1, 2 or 5 pmol) promoted hypotension and reduction in sympathetic vasomotor tone in a dose-related manner (Fig. 3). In contrast, the same doses of DPN (2 or 5 pmol) microinjected outside the confine of RVLM (e.g., spinal trigeminal nucleus or lateral paragigantocellular nucleus) caused a minimal alteration in the same cardiovascular parameters (data not shown). In a separate series of experiments, microinjection bilaterally into the RVLM of ERalpha agonist PPT (5 pmol) did not affect basal hemodynamic parameters (Fig. 3). Similarly, intravenous injection of DPN (5 pmol) did not affect the baseline MSAP, HR or power density of vasomotor components of SAP spectrum (MSAP: -4.1 +/- 1.2 mmHg; HR: +4.4 +/- 1.1 bpm; SAP spectrum: -0.7 +/- 0.5 mmHg2, n = 3).
###end p 41
###begin p 42
###xml 0 98 0 91 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cardiovascular effects after microinjection bilaterally into the RVLM of ER&#945; or ER&#946; agonist</bold>
###xml 433 435 424 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 231 235 <span type="species:ncbi:10116">rats</span>
Cardiovascular effects after microinjection bilaterally into the RVLM of ERalpha or ERbeta agonist. Time-course of the changes in MSAP, HR and total power density of vasomotor components (0-0.8 Hz) of SAP spectrum in anaesthetized rats that received microinjection bilaterally into the RVLM (at time 0) of aCSF, DPN (1, 2 or 5 pmol), or PPT (5 pmol). Values are presented as mean +/- S.E.M., n = 6-8 animals per experimental group. *P < 0.05 versus corresponding aCSF group in the Scheffe multiple range test.
###end p 42
###begin title 43
Effects of NOS inhibitor on the ERbeta agonist-induced cardiovascular depressive effects
###end title 43
###begin p 44
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 547 548 547 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 775 776 775 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Compared with the aCSF or 3% MeOH controls, co-administration of the nonselective NOS inhibitor, L-NAME (5 nmol) significantly attenuated hypotension and reduction in power density of vasomotor components of SAP spectrum promoted by microinjection bilaterally into the RVLM of DPN (2 pmol) (Fig. 4). Of the three isoforms of NOS, we found that only the iNOS inhibitor SMT (25 pmol), but not the nNOS inhibitor 7-NI (0.5 pmol) or the eNOS inhibitor L-NIO (2.5 pmol), appreciably attenuated the DPN-induced cardiovascular depressive responses (Fig. 4). Microinjection into bilateral RVLM of L-NAME (5 nmol), SMT (25 pmol), 7-NI (0.5 pmol), or L-NIO (2.5 pmol) alone had no significant effect on baseline MSAP, HR or power density of vasomotor components of SAP spectrum (Table 1).
###end p 44
###begin p 45
###xml 0 88 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effects of NOS inhibitor on the ER&#946; agonist-induced cardiovascular depressive effects</bold>
###xml 501 503 496 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 547 548 542 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 548 550 543 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 217 221 <span type="species:ncbi:10116">rats</span>
Effects of NOS inhibitor on the ERbeta agonist-induced cardiovascular depressive effects. Time-course of the changes in MSAP and total power density of vasomotor components (0-0.8 Hz) of SAP spectrum in anaesthetized rats that received microinjection bilaterally into the RVLM (at time 0) of aCSF, 3% methanol (MeOH), or DPN (2 pmol) given together with L-NAME (5 nmol), SMT (25 pmol), 7-NI (0.5 pmol), L-NIO (2.5 pmol) or 3% MeOH. Values are mean +/- S.E.M., n = 6-7 animals per experimental group. *P < 0.05 versus corresponding MeOH group, and #P < 0.05 versus corresponding DPN+MeOH group in the Scheffe multiple range test. Data on aCSF are not shown because they in essence duplicated those by 3% MeOH.
###end p 45
###begin title 46
Microinjection sites
###end title 46
###begin p 47
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 401 403 398 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Histological verification of locations of micropipette tips in the ventrolateral medulla confirmed that all observations were made from animals that received local administration of the test agents within the anatomic confines of the RVLM (Fig. 5). For the purpose of clarity, Fig. 5 only summarizes the location of sites where microinjection of E2beta (5 pmol) and DPN (5 pmol) elicited significant (P < 0.05) inhibitory effects on the MSAP and power density of vasomotor components of SAP spectrum.
###end p 47
###begin p 48
###xml 0 50 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Microinjection sites of E2&#946; and DPN in the RVLM</bold>
Microinjection sites of E2beta and DPN in the RVLM. Diagrammatic representations of two rostral-caudal levels of the RVLM (dotted line areas) with reference to the lambda illustrating the location of sites where bilateral microinjection of E2beta (black circle, 5 pmol) and DPN (â—¦,5 pmol) elicited significant inhibitory or minimal effects (black square, non-RVLM microinjection sites) on the MSAP and power density of vasomotor components of SAP spectrum. Numbers on right side indicate distance from the lambda. For the purpose of clarity, approximately 20% of the total microinjection sites are included and are presented on both side of the diagram. ION, inferior olivary nucleus; NA, nucleus ambiguous; NTS, nucleus tractus solitarii; RVLM, rostral ventrolateral medulla; V, nucleus of the spinal trigeminal nerve; py, pyramidal tract.
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
To the best of our knowledge, the present study is the first demonstration of an active role of ERbeta at the RVLM in central cardiovascular regulation. We found that E2beta and ERbeta agonist dose-dependently decreased MSAP and power density of vasomotor components of SAP spectrum, whereas ERalpha agonist did not change these hemodynamic parameters. We further demonstrated that the iNOS-derived NO in the RVLM is involved in the ERbeta-dependent cardiovascular depressive effects.
###end p 50
###begin p 51
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 148 149 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 200 202 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 224 226 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 227 229 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 836 838 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Accumulative evidence indicates estrogen as an active hormone in central cardiovascular regulation [9-14] via activation of the ERalpha and ERbeta [1]. Within the brain stem, ERalpha and ERbeta mRNA [15] as well as protein [16,17]are expressed in the RVLM. Function of these RVLM neurons expressing ERs, however, is not fully understood. One major finding of the present study is the identification of a short-term vasodepressor effect of estrogen in the RVLM. A lower dose (0.5 pmol) of E2beta promoted acute vasodepressor responses that lasted for 150 min postinjection, whereas at higher doses (1 or 5 pmol) E2beta produced similar effects that sustained more than 3-4 hrs postinjection. It has been reported that direct microinjection of the same steroid hormone (0.5 muM) into the RVLM produces a short-term (<60 min) hypotension [13]. These results suggest that the duration of short-term vasodepressor effects of E2beta in the RVLM is manifested in a dose-dependent manner. Long-term (>24 hrs) cardiovascular effect of E2beta in the RVLM and the involvement of nongenomic and/or genomic signaling mechanisms, however, await further investigation. In addition, we demonstrated that these cardiovascular regulatory effects of the female steroids are nucleus specific, since application of E2beta or its agonist, DPN, to areas outside the confines of the RVLM did not influence the baseline hemodynamics. More importantly, we found that high dose E2beta or DPN promoted cardiovascular depression only when they were microinjected into the bilateral RVLM but not intravenously. These findings confirmed that the E2beta- and DPN-induced cardiovascular depressive responses are not caused by leakage of these test agents from the injection site in the brain to the peripheral circulation.
###end p 51
###begin p 52
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1530 1533 1482 1485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">++ </sup>
###xml 1624 1626 1569 1571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1825 1827 1764 1766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 2004 2006 1936 1938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 2452 2453 2375 2376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 2454 2456 2377 2379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2472 2473 2395 2396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 2474 2475 2397 2398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 2590 2591 2513 2514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 2592 2593 2515 2516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 2594 2595 2517 2518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 316 320 <span type="species:ncbi:10116">rats</span>
###xml 1659 1663 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
There are only a limited data from in vivo studies to demonstrate the role of estrogen in central cardiovascular regulation. Consistent with our observation, a previous study [13] reported that direct microinjection of E2beta into the RVLM elicits significant decreases in SAP and sympathetic nerve activity in male rats, suggesting that estrogen participate in central cardiovascular regulation by acting directly on the RVLM. At receptor level, we found that the cardiovascular depressive effects of E2beta are mediated via activation of the ERbeta in the RVLM. The nonselective ER antagonist ICI 182780, at the dose that did not by itself alter the baseline circulatory parameters implying that endogenous estrogen may not exerts a tonic effect on the cardiovascular responses at the level of the RVLM, whereas this antagonist almost completely reversed the cardiovascular depressive effects by E2beta. Furthermore, we also demonstrate that the cardiovascular depressive effects induced by selective ERbeta agonist DPN, but not the selective ERalpha agonist PPT, are similar to that induced by E2beta. We also employed specific ERalpha or ERbeta antagonist to demonstrate engagement of ERbeta but not ERalpha in the E2beta-mediated vasodepressor effects in the RVLM. These results suggest that E2beta in the RVLM induces vasodepressor effects mainly via the ERbeta-mediated mechanisms. This suggestion is supported by the study that in the isolated RVLM neurons, E2beta possesses rapid inhibitory effect on the voltage-gated Ca++ currents, which is mimicked by the ERbeta-selective but not the ERalpha-selective agonist [17]. Additionally, ERbeta knockout mice exhibit sustained hypertension and abnormal vascular function indicating an essential role for ERbeta in the regulation of vascular function and blood pressure [27]. Anatomically, the distribution of ERbeta-immunoreactivity in the RVLM neurons is prominent in the extra-nuclear sites than that of ERalpha, particularly on plasma membranes [17]. The observed short-term hypotension and reduction in sympathetic vasomotor tone, which occurred approximately 30 min after microinjection of E2beta or ERbeta agonist into the RVLM, may therefore mediated by a nongenomic signaling mechanism. In support of this suggestion, we found that transcription inhibitor, AMD, did not affect the E2beta-induced short-term vasodepressor response. The rapid nongenomic actions of estrogen in both cardiac [7,28] and vascular [4,5] systems are mediated directly by ERs located in or close to the cellular membrane rather than the nuclear sites [3,4,8]. Cellular mechanism underling the ERbeta-mediated short-term cardiovascular effect in the RVLM, however, awaits further investigation.
###end p 52
###begin p 53
###xml 246 248 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 249 251 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 252 254 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 403 405 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 406 408 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 409 411 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 998 1000 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1180 1182 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1331 1333 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1618 1620 1603 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1621 1623 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1624 1626 1609 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1957 1959 1939 1941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 2025 2027 2007 2009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1055 1059 <span type="species:ncbi:10116">rats</span>
Another major contribution of this study is to demonstrate the involvement of NO in cardiovascular depression induced by activation of ERbeta in the RVLM. NO is a well-established neuromodulator for central cardiovascular regulation in the RVLM [26,29-34]. Microinjection of the NO precursor or donor into the RVLM reportedly produces prominent depressor effects and reduced sympathetic nerve activity [26,29-31]. In the present study we found that the ERbeta agonist-induced cardiovascular depressive responses were attenuated by co-administration of the nonselective NOS inhibitor, L-NAME. These results indicate that NO is engaged in cardiovascular depression induced by activation of ERbeta and further imply that cardiovascular depressive responses of estrogen may be mediated via an interaction between estrogen and NO signals in the RVLM. This suggestion is supported by the study that estrogen alters the NOS expression via activation of ERbeta in the hypothalamic paraventricular nucleus [35]. In addition, estrogen replacement in ovariectomized rats reduces arterial pressure responses to psychological stress by increasing NO production in brain stem and hypothalamus [36]. Intracarotid injection of estrogen inhibits spontaneous electrical activity of RVLM neurons via the activation of NO-dependent signaling pathway [37]. Of the three isoforms of NOS that have been identified in the RVLM, we found that NO derived from iNOS may play a major role in the ERbeta-dependent cardiovascular depression. The iNOS-derived NO in the RVLM has been reported to elicit sympathoinhibition and vasodepressor effects [26,33,34]. A negative result of 7-NI or L-NIO, on the other hand, implies a minor role of nNOS and eNOS in the ERbeta-dependent cardiovascular depression in the RVLM. At a lower dose than those used in the present study, 7-NI or L-NIO has been reported to selective inhibit the nNOS-derived NO in the hypothalamic paraventricular nucleus [38] or L-arginine-induced NO synthesis in the vascular endothelium [39]. We noted that L-NAME or iNOS inhibition did not completely attenuate the cardiovascular depressive responses induced by ERbeta agonist. The involvement of NO-independent alternative pathways in the cardiovascular depressive effects of E2beta in the RVLM, therefore, awaits further investigation.
###end p 53
###begin p 54
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 516 518 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 519 521 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 522 524 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 643 645 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 646 648 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 649 651 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 817 819 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1057 1059 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1060 1062 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1266 1268 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 136 140 <span type="species:ncbi:10116">rats</span>
###xml 366 370 <span type="species:ncbi:10116">rats</span>
To avoid confounding cardiovascular effects caused by differing levels of circulating estrogen through various stages in cycling female rats, we purposely selected male animals in the present study. In addition, a number of previous studies on the rapid cardiovascular effects of estrogen in the RVLM [13] or other central autonomic nuclei [13,40] were done in male rats. PPT and DPN are reported to be a useful experimental tool to study the differences in structure and biological functions of ERalpha and ERbeta [17,41,42]. The selectivity of nonsteroidal estrogen, PPT and DPN as respective ERalpha and ERbeta agonist has been documented [17,41,42]. PPT and DPN exhibits a relative high selectivity toward ERalpha and ERbeta, respectively, when compared with some phytoestrogens such as genistein and coumestrol [43]. We also realize that this study was conducted under an anesthetic condition that may be a major confounding factor to the observed cardiovascular responses. This possibility, however, is deem unlikely since we demonstrated previously [19,20] that the anesthetic maintenance scheme (i.e., propofol at 20-30 mg/kg/h) used in this study has no discernible effect on the sympathetic vasomotor outflow from the RVLM, and hence baseline MSAP and HR [21].
###end p 54
###begin p 55
In conclusion, our results demonstrate that the E2beta in the RVLM elicited short-term non-genomic cardiovascular inhibitory effects via activation of ERbeta. Furthermore, NO derived from iNOS may contribute to central vasodepressor effects after activation of ERbeta in the RVLM.
###end p 55
###begin title 56
Competing interests
###end title 56
###begin p 57
The author declares that they have no competing interests.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
CDS participated in experimental conception and design, performed animal and pharmacological experiments, acquisition of data, the statistical analysis and interpretation of data, and was also involved in drafting and revising the manuscript and have given final approval of the version to be published.
###end p 59
###begin p 60
Author read and approved the final manuscript.
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
This study was supported by Tajen research grants 96059 from the Tajen University, Pingtung, Taiwan, Republic of China.
###end p 62
###begin article-title 63
Cell localization, physiology, and nongenomic actions of estrogen receptors
###end article-title 63
###begin article-title 64
Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors
###end article-title 64
###begin article-title 65
Rapid actions of plasma membrane estrogen receptors
###end article-title 65
###begin article-title 66
Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase
###end article-title 66
###begin article-title 67
Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta
###end article-title 67
###begin article-title 68
###xml 72 79 <span type="species:ncbi:9986">rabbits</span>
Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: possible mechanisms for gender differences in atherosclerosis
###end article-title 68
###begin article-title 69
Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels
###end article-title 69
###begin article-title 70
Functional significance of the rapid regulation of brain estrogen action: where do the estrogens come from?
###end article-title 70
###begin article-title 71
###xml 57 61 <span type="species:ncbi:10116">rats</span>
Central vasopressor responses to conjugated estrogens in rats may be mediated via a renin-angiotensin system in the brain
###end article-title 71
###begin article-title 72
Estrogen enhancement of baroreflex sensitivity is centrally mediated
###end article-title 72
###begin article-title 73
###xml 78 82 <span type="species:ncbi:10116">rats</span>
Centrally mediated effect of 17beta-estradiol on parasympathetic tone in male rats
###end article-title 73
###begin article-title 74
###xml 79 83 <span type="species:ncbi:10116">rats</span>
17beta-estradiol modulates baroreflex sensitivity and autonomic tone of female rats
###end article-title 74
###begin article-title 75
###xml 65 69 <span type="species:ncbi:10116">rats</span>
Medullary and intrathecal injections of 17beta-estradiol in male rats
###end article-title 75
###begin article-title 76
###xml 101 105 <span type="species:ncbi:10116">rats</span>
Autonomic and cardiovascular reflex responses to central estrogen injection in ovariectomized female rats
###end article-title 76
###begin article-title 77
###xml 74 77 <span type="species:ncbi:10116">rat</span>
Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system
###end article-title 77
###begin article-title 78
###xml 63 66 <span type="species:ncbi:10116">rat</span>
Distribution of estrogen receptor beta immunoreactivity in the rat central nervous system
###end article-title 78
###begin article-title 79
Evidence that estrogen directly and indirectly modulates C1 adrenergic bulbospinal neurons in the rostral ventrolateral medulla
###end article-title 79
###begin article-title 80
Tonic vasomotor control by the rostral ventrolateral medulla: effect of electrical or chemical stimulation of the area containing C1 adrenaline neurons on arterial pressure, heart rate, and plasma catecholamines and vasopressin
###end article-title 80
###begin article-title 81
Differential role of leptin receptors at the hypothalamic paraventricular nucleus in tonic regulation of food intake and cardiovascular functions
###end article-title 81
###begin article-title 82
###xml 114 118 <span type="species:ncbi:10116">rats</span>
Nitric oxide and GABA mediate bi-directional cardiovascular effects of orexin in the nucleus tractus solitarii of rats
###end article-title 82
###begin article-title 83
###xml 135 138 <span type="species:ncbi:10116">rat</span>
Effects of propofol on nociceptive response and power spectra of electroencephalographic and systemic arterial pressure signals in the rat: correlation with plasma concentration
###end article-title 83
###begin article-title 84
Comparative effects of thiopentone and propofol on respiratory resistance after tracheal intubation
###end article-title 84
###begin article-title 85
###xml 105 108 <span type="species:ncbi:9615">dog</span>
Propofol and methohexital have no significant effect on mucus secretion or clearance in the anesthetized dog
###end article-title 85
###begin article-title 86
Continuous, on-line, real-time spectral analysis of systemic arterial pressure signals
###end article-title 86
###begin article-title 87
###xml 102 106 <span type="species:ncbi:10116">rats</span>
Selective activation of vasomotor component of SAP spectrum by nucleus reticularis ventrolateralis in rats
###end article-title 87
###begin article-title 88
###xml 106 109 <span type="species:ncbi:10116">rat</span>
Differential cardiovascular responses to blockade of nNOS or iNOS in rostral ventrolateral medulla of the rat
###end article-title 88
###begin article-title 89
###xml 47 51 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta
###end article-title 89
###begin article-title 90
The PI3K/Akt pathway mediates the nongenomic cardioprotective effects of estrogen following trauma-hemorrhage
###end article-title 90
###begin article-title 91
Inhibition of basal and reflex-mediated sympathetic activity in the RVLM by nitric oxide
###end article-title 91
###begin article-title 92
###xml 67 71 <span type="species:ncbi:10116">rats</span>
Cardiovascular effects of nitric oxide in the brain stem nuclei of rats
###end article-title 92
###begin article-title 93
###xml 79 83 <span type="species:ncbi:10116">rats</span>
Cardiovascular effects of nitric oxide in the rostral ventrolateral medulla of rats
###end article-title 93
###begin article-title 94
Overexpression of eNOS in the RVLM causes hypotension and bradycardia via GABA release
###end article-title 94
###begin article-title 95
###xml 104 107 <span type="species:ncbi:10116">rat</span>
Differential distribution of nitric oxide synthase isoforms in the rostral ventrolateral medulla of the rat
###end article-title 95
###begin article-title 96
###xml 131 135 <span type="species:ncbi:10116">rats</span>
Differential influence of iNOS and nNOS inhibitors on rostral ventrolateral medullary mediated cardiovascular control in conscious rats
###end article-title 96
###begin article-title 97
Estrogen modulates endothelial and neuronal nitric oxide synthase expression via an estrogen receptor beta-dependent mechanism in hypothalamic slice cultures
###end article-title 97
###begin article-title 98
###xml 102 106 <span type="species:ncbi:10116">rats</span>
NO mediates effects of estrogen on central regulation of blood pressure in restrained, ovariectomized rats
###end article-title 98
###begin article-title 99
###xml 128 132 <span type="species:ncbi:10116">rats</span>
Effects of intracarotid injection of 17beta-estradiol on electrical activity of rostral ventrolateral medullary neurons in male rats
###end article-title 99
###begin article-title 100
Decrease in arterial pressure induced by adrenomedullin in the hypothalamic paraventricular nucleus is mediated by nitric oxide and GABA
###end article-title 100
###begin article-title 101
###xml 74 83 74 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo
###end article-title 101
###begin article-title 102
###xml 100 104 <span type="species:ncbi:10116">rats</span>
Central nuclei mediating estrogen-induced changes in autonomic tone and baroreceptor reflex in male rats
###end article-title 102
###begin article-title 103
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists
###end article-title 103
###begin article-title 104
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues
###end article-title 104
###begin article-title 105
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
###end article-title 105

